Group 1 - The Hang Seng Index opened flat, while the Hang Seng Tech Index fell by 0.04%. Notably, tech stocks were active with Meituan rising by 1.08% and Baidu Group increasing by 0.91%. In the pharmaceutical sector, Fosun Pharma surged by 4.19% [1] - Haitong International believes that after market consolidation, a rebound is expected to continue, with room for tech recovery. The firm suggests that the rebound's strength will depend on policy implementation and potential interest rate cuts by the Federal Reserve. There is a caution regarding the risk of profit-taking if the market anticipates good news too early [1] - Everbright Securities indicates that after a rebound in 2025, the current valuation of the Hang Seng Index is above its 5-year average, reflecting a reasonable valuation range. The tech index has just returned to its 5-year average, suggesting there is still room for valuation catch-up. The firm predicts that the Hang Seng Index could exceed 30,000 points next year [1] Group 2 - Guotai Junan Securities states that the short-term adjustment in the Hong Kong stock market opens up space for a market rise in 2026. In terms of capital flow, over 110 billion RMB of southbound funds have net flowed into the Hong Kong stock market in November. This indicates strong liquidity and a strong willingness from mainland investors to position themselves in the Hong Kong market at lower levels [2] - The firm forecasts that the Hong Kong stock market could operate between 30,000 and 32,000 points in 2026 [2]
港股开盘 | 恒生指数平开 科网股活跃 医药股分化
智通财经网·2025-12-10 01:37